MedPath

Investigations on biomarker search in patients with non-small-cell bronchial carcinoma under checkpoint inhibitor therapy

Conditions
C34.9
Bronchus or lung, unspecified
Registration Number
DRKS00022767
Lead Sponsor
Krankenhaus Martha-Maria Halle-Dölau
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
92
Inclusion Criteria

Patients must be able to give consent themselves
- signed consent form
- histologically confirmed NSCLC with indication for palliative immunotherapy with or without chemotherapy

Exclusion Criteria

- histologically confirmed SCLC
- previous immunotherapies

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
progressionfree survival<br>- controll via CT and MRI after 4th cycle of immunotherapy and afterwards every 3 month or if there is clinical indication of progress
Secondary Outcome Measures
NameTimeMethod
Overall survival<br>- controll every 3 month<br>- acquiation via Klinisches Krebsregister or genaral practitioner
© Copyright 2025. All Rights Reserved by MedPath